TY - JOUR
T1 - Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy
AU - Matthews, Dennis J.
AU - James, Katherine A.
AU - Miller, Lisa A.
AU - Pandya, Shree
AU - Campbell, Kimberly A.
AU - Ciafaloni, Emma
AU - Mathews, Katherine D.
AU - Miller, Timothy M.
AU - Cunniff, Christopher
AU - Meaney, F. John
AU - Druschel, Charlotte M.
AU - Romitti, Paul A.
AU - Fox, Deborah J.
PY - 2010/11
Y1 - 2010/11
N2 - The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20% (11 of 56 individuals) in 1991 to 44% (93 of 218 individuals) in 2005. Average use varied by site and ranged from 15% to 49%. The median age of corticosteroid initiation was 6.9 years (range, 3.7-17.4 years). Dosage and growth information was available for 102 participants and showed a median dose as 0.729 mg/kg for prednisone and 0.831 mg/kg for deflazacort. T. The most common reasons that corticosteroids were discontinued included weight gain, behavioral side effects, and loss of ambulation, resulting in full-time wheelchair use. Substantial variations in clinical practice were identified among study sites.
AB - The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20% (11 of 56 individuals) in 1991 to 44% (93 of 218 individuals) in 2005. Average use varied by site and ranged from 15% to 49%. The median age of corticosteroid initiation was 6.9 years (range, 3.7-17.4 years). Dosage and growth information was available for 102 participants and showed a median dose as 0.729 mg/kg for prednisone and 0.831 mg/kg for deflazacort. T. The most common reasons that corticosteroids were discontinued included weight gain, behavioral side effects, and loss of ambulation, resulting in full-time wheelchair use. Substantial variations in clinical practice were identified among study sites.
KW - Becker muscular dystrophy
KW - Duchenne muscular dystrophy
KW - corticosteroids
KW - population-based studies
UR - http://www.scopus.com/inward/record.url?scp=78650186613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650186613&partnerID=8YFLogxK
U2 - 10.1177/0883073810362762
DO - 10.1177/0883073810362762
M3 - Article
C2 - 20207610
AN - SCOPUS:78650186613
SN - 0883-0738
VL - 25
SP - 1319
EP - 1324
JO - Journal of Child Neurology
JF - Journal of Child Neurology
IS - 11
ER -